Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500278 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
A Phase 4 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 915
- Enrollment target
NCT01500278 is a Phase 4 study that has completed, run by UCB Pharma. The registered enrollment target is 915 participants.
The verdict
NCT01500278, a Phase 4 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 915 participants
- Enrollment target
Study Summary
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.
Interventions
- DRUG Methotrexate (MTX)
- BIOLOGICAL Adalimumab (ADA)
- BIOLOGICAL Certolizumab Pegol (CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 915 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500278
The ClinicalTrials.gov registry entry for NCT01500278 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 915 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methotrexate (MTX) is the first listed.
NCT01500278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01500278 about?
NCT01500278 is a clinical study titled "Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate". This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.
What is the current status of trial NCT01500278?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 915 participants. The study started on 2011-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01500278?
The interventions under investigation include: Methotrexate (MTX) (DRUG), Adalimumab (ADA) (BIOLOGICAL), Certolizumab Pegol (CZP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01500278?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.